drugset / Trial / NCT00765726

Study Evaluating The Safety Of Xyntha In Usual Care Settings

NCT00765726

Phase 4 Terminated 12 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect safety information associated with the use of Xyntha in a usual care setting. Upon meeting eligibility criteria, patients will be required to have approximately 5 study visits over a 2 year period. Procedures completed throughout the study include collection of vital signs, physical exams, and laboratory assessments. Patients will be required to complete an infusion log for each Xyntha infusion.

Timeline

Start
2009-02
Primary completion
2011-07
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Moroctocog alfa Protein / enzyme biologic

Indications